Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.16 EUR
Change Today -1.45 / -2.56%
Volume 835.0
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
Mexico
Berlin
As of 5:08 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€56.20
Previous Close
€56.61
Day High
€56.64
Day Low
€54.35
52 Week High
04/23/15 - €69.06
52 Week Low
10/16/14 - €51.81
Market Cap
69.7B
Average Volume 10 Days
4.9K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/15
P/E TM
--
Dividend
€3.10
Dividend Yield
4.99%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (ZEG) Key Developments

AstraZeneca PLC and Peregrine Pharmaceuticals, Inc. to Collaborate on Immuno-Oncology Combination Clinical Trial

AstraZeneca PLC and Peregrine Pharmaceuticals, Inc. announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine’s investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors. Peregrine and AstraZeneca will collaborate on a non-exclusive basis, to evaluate the combination of bavituximab and durvalumab with chemotherapy as a potential treatment in various solid tumors. The Phase I part of the trial is expected to establish a recommended dose regimen for the combination and the Phase Ib part of the trial will assess the safety and efficacy of the investigational combination. Under the terms of the agreement, the initial trial will be conducted by Peregrine. Bavituximab and durvalumab are investigational immunotherapies with different mechanisms that assist the body's immune system in fighting cancer. Bavituximab targets and modulates the activity of phosphatidylserine, a highly immune-suppressive molecule expressed broadly on the surface of cells in the tumor microenvironment. The treatment increases activated T-cells in tumors and fights cancer by reversing the immunosuppressive environment that many tumors establish in order to proliferate. MEDI4736 is a monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. Preclinical data have demonstrated that combining the enhanced T-cell mediated anti-tumor activity of bavituximab with checkpoint inhibitors, like PD-L1 antibodies, prolong the ability of tumor-specific T-cells to continue attacking the tumor.

AstraZeneca Appoints Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer, Effective September 15, 2015

AstraZeneca announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September. Dr. Bohen will be responsible for driving the progress of AstraZeneca's portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As Chief Medical Officer, he will be responsible for patient safety across the entire AstraZeneca and Medimmune portfolio. Dr. Bohen joins AstraZeneca from Genentech where he was most recently Senior Vice President of Early Development.

AstraZeneca and Heptares Therapeutics Partner to Develop New Immuno-Oncology Treatments

AstraZeneca has signed a licencing agreement with Heptares Therapeutics to develop novel immuno-oncology treatments. Under the deal, AstraZeneca will acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Both the firms will also work together to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €55.16 EUR -1.45

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $142.14 USD -2.07
Abbott Laboratories $45.29 USD -0.73
Biogen Inc $297.30 USD -6.39
Eli Lilly & Co $82.35 USD -0.84
Valeant Pharmaceuticals International Inc C$304.99 CAD -7.06
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 68.0x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.9x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.